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Abstract
Background: An accurate, practical laboratory test is needed to confirm clinical diagnosis of
pertussis in adults during the first 3 symptomatic weeks, when treatment is effective and
transmission can be interrupted.
Methods: The sensitivity and specificity of single IgA and IgG levels were assessed in a cohort study
of a pertussis epidemic in 99 adults in a closed community. Sensitivities were assessed in the sera
of 46 laboratory confirmed clinical pertussis cases during the first 3 weeks. Specificities were
calculated in sera of 35 asymptomatic controls without clinical symptoms or laboratory confirmed
infections from the same community (internal controls). We compared these specificities with the
specificities of single IgA and IgG levels in 4275 external controls from a cross-section of the general
Dutch population aged 21–79 years who had not coughed for more than 2 weeks in the past year,
and without pertussis diagnoses. The study was done in the Netherlands when whole-cell pertussis
vaccine was used in the national vaccination programme.
Results: Levels of 24 U/ml for IgA and 27 U/ml for IgG gave sensitivities of 100% and 75%,
respectively, in the first 2 weeks, 100% in the third week, and 97% after the fourth week. The levels
were reached within 2 days after onset of increase, and remained above these levels for roughly
7.2 and 5.1 months, respectively. Specificity was 82% for IgA and 89% for IgG in the internal
controls and 90% in the external controls, respectively.
Conclusion: We suggest levels of 24 U/ml for IgA level and 27 U/ml (= 27 International Units (IU)/
ml) for IgG as sensitive, specific, and practical for laboratory confirmation of clinical pertussis in
adults in the first 3 weeks of outbreak management.
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Background
Pertussis is a bacterial infection caused by Bordetella pertus-
sis. Despite the introduction of mass vaccinations in the
Netherlands in 1952 and other countries, pertussis is still
an endemic disease with regular epidemic outbreaks.[1-5]
In unvaccinated populations, pertussis morbidity and
mortality occur predominantly in those 15 years or
younger.[6] In vaccinated populations, pertussis is more
likely to be found in older children and adults.[7-13] Cir-
culation of Bordetella pertussis in vaccinated children, ado-
lescents, and adults plays an important role in the
continuing transmission of the pathogen to infants too
young to be vaccinated, in whom the disease is the most
severe and sometimes fatal.[14-19]
Pertussis is most infectious in its prodromic and early clin-
ical stages. Effective management in unvaccinated infants
and during outbreaks requires early diagnosis and treat-
ment of cases, accompanied by antibiotic prophylaxis of
contacts.[20,21] There is no evidence of benefit from che-
moprophylaxis given more than 21 days after the onset of
the primary case.[22,23] Therefore, antibiotic manage-
ment of pertussis should be initiated promptly to mini-
mize secondary spread.[24] For the improvement of
clinical diagnosis and pertussis surveillance, rapid, easily
accessible, highly sensitive and specific laboratory meth-
ods are needed to diagnose pertussis in the first 3
weeks.[25] The validity of methods for pertussis diagnosis
depends on the time of initiation. Early in the disease, cul-
ture and PCR can be used. Culture of B. pertussis is highly
specific, but laborious and insensitive.[26] The yield pro-
gressively decreases during disease[27] and is low after 2
weeks and antibiotic use.[28] The sensitivity of PCR is
superior, but rapidly decreases with increasing duration of
the disease and patient age.[29,30] Serology is a good
alternative.[29,31,32] In this study, we assessed the sensi-
tivity and specificity of single IgA and IgG antibody levels
for laboratory confirmation of clinical pertussis in adults
during the first 3 weeks of symptoms. The study was done
in the Netherlands when whole-cell pertussis vaccine was
used in the national vaccination programme.
Methods
Study population
The clinical and laboratory outcomes of a pertussis epi-
demic in a religious convent, which has been described
previously, was used as a sample population to evaluate
single IgA and IgG levels after other causes for an outbreak
of coughing were excluded.[12] In short, the epidemic
was reported to the Municipal Public Health Service
(MPHS) in its 9th week for outbreak management, at
which time the study began. The convent was a nursing
home for 75 elderly resident nuns supported by 24 non-
resident personnel. The personnel consisted of 3 males
and 21 females. The mean age was 75 years (range 55–94
years) for the nuns and 27 years (range 21–46 years) for
the personnel. All of the nuns and 5 of 24 non-resident
personnel had never been vaccinated against pertussis.
The nuns and staff shared common social and religious
activities, and shared meals in the dining room. Pertussis
cases were cared for in the convent by nuns and person-
nel. Retrospective interviews based on structured ques-
tionnaires were conducted to obtain information about
the onset of characteristic clinical symptoms in the first 9
weeks of the epidemic. The emergence and duration of the
clinical manifestations were prospectively monitored
daily from week 9 up to week 13, the period that the epi-
demic persisted with new cases. After week 13, cases were
monitored weekly until symptoms subsided. Two
nasopharyngeal swabs were obtained from each individ-
ual at weeks 9 and 13 of the epidemic, one for culture and
one for PCR. At weeks 9, 13, and 60 serum samples were
obtained to determine IgA and IgG antibody levels.
Definitions
Laboratory confirmed B. pertussis infection was defined as
one of the laboratory findings: 1) B. pertussis strain iso-
lated from the nasopharynx; 2) reactive PCR; 3) signifi-
cant (at least 4-fold) increases or decreases[33,34] of IgA
or IgG antibody levels between at least one pair of serum
samples obtained at weeks 9, 13, and 60 of the epidemic;
and 4) IgG level  100 U/ml at weeks 9 or 13 of the epi-
demic[35] (equivalent to 125 International Units (IU)/
ml).[12] We defined clinical pertussis as a persistent cough
and its duration was divided in "7–13 days" and "at least
14 days".[36] Pertussis cases had both laboratory con-
firmed  B. pertussis infection and clinical pertussis. The
index case was the first pertussis case in the epidemic. Pre-
epidemic cough was defined as a cough that occurred before
the emergence of the index case. Internal controls had no
laboratory confirmed B. pertussis infection and were
asymptomatic residents or non-resident personnel, i.e.
they had no pre-epidemic cough nor clinical pertussis.
Sensitivities of different IgA and IgG levels were calculated
as the proportion of serum samples with a positive test
result. The calculations were done in samples obtained
from pertussis cases who had coughed for at least one day
during their period of clinical pertussis. Specificities of dif-
ferent IgA and IgG levels were calculated as the proportion
of serum samples with a negative test result. These calcu-
lations were done in samples obtained from the internal
controls. Specificities were also calculated in 4275 exter-
nal controls from a cross-section of the general Dutch
population in the same age group (21–79 years) as the
convent population. Control subjects reported in a struc-
tured questionnaire to have not coughed for more than 2
weeks in the past year, nor to have had a physician-diag-
nosed pertussis.[35,37] From the external controls, specif-
icities of different IgA and IgG levels were calculated as theBMC Infectious Diseases 2007, 7:53 http://www.biomedcentral.com/1471-2334/7/53
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proportion of the 4275 serum samples with a negative test
result.
The duration of waxing and waning of IgA and IgG 
concentrations
To estimate the time period after which single IgA and IgG
concentrations can be reused as a diagnostic test for a sub-
sequent pertussis infection, we assessed the duration (in
days) of waxing and waning of IgA and IgG concentra-
tions after a B. pertussis infection. Therefore we first calcu-
lated the geometrical mean concentration (GMC, U/ml)
over the highest IgA and IgG levels obtained in week 9 and
13 of the epidemic for all subjects with a significant
increase or decrease of antibody level. In these subjects we
then calculated the mean rate of increase (expressed as U/
ml/day) towards the GMC and the mean rate of decrease
from the GMC downwards. This was done for IgA and IgG
separately.
Laboratory methods
In the two populations, the serological laboratory investi-
gation of pertussis specific IgA and IgG antibodies was
performed by enzyme-linked immunosorbent assay
(ELISA) at the National Institute for Public Health and the
Environment (RIVM), the Netherlands, as described pre-
viously.[12,31,35,38] For IgA class antibody detection, a
crude cell-wall preparation of B. pertussis was used. For
IgG class antibody detection, purified pertussis toxin was
used. Antibody binding activities were quantitatively
expressed in 'local' units per milliliter (U/ml). IgG can be
converted to FDA international units (IU) non-linearly by
the formula Log10(U/ml) = 0.2174 + 0.8475log10(IU/
ml).[39,40] The detection limit of the assays was 5 U/
ml.[35] In our evaluation of sensitivities and specificities
of single IgA and IgG levels, we focused on levels at least
4 times the detection limit. Culture and PCR were proc-
essed as described previously.[12,30,41]
Results
Convent population
The convent population consisted of 75 nuns and 24 per-
sonnel. All 99 individuals participated in the study. The
pertussis epidemic started in week 1 with the emergence
of the first case with laboratory confirmed pertussis infec-
tion. The last case was detected in week 13. During the
study, 6 residents died resulting in 99, 99, and 93 study
subjects in weeks 9, 13, and 60 of the epidemic, respec-
tively.
Clinical outcome
Retrospective evaluation of weeks 1–9 of the epidemic
revealed 2 subjects with a pre-epidemic cough, 3 subjects
with clinical pertussis of 7–13 days duration, and 41 with
clinical pertussis coughing 14 days or more. Prospective
evaluation in weeks 9–13 of the epidemic revealed
another 6 subjects with clinical pertussis coughing 14 days
or more and 47 with no cough (Table 1). Clinical pertus-
sis persisted for a mean period of 69 days (range: 7 – 268
days).
Laboratory outcome
At weeks 9, 13, and 60 of the epidemic 94, 97, and 85
serum samples, respectively, were obtained. Three sam-
ples were collected from 80 subjects, and 2 from 17 sub-
Table 1: Outcome of clinical and laboratory investigations in absolute numbers in the convent population (N = 99)
Outcome of laboratory tests for pertussis infection Clinical Outcome Total
Clinical pertussis 
coughing > 14 days
Clinical pertussis 
coughing 7–13 days
Pre-epidemic cough  No cough 
 (n = 47)c  (n = 3)c (n = 2) (n = 47)e (N = 99)
Laboratory confirmed pertussis infection: 45b 1b 01 2 f 58
IgA or IgG 4-fold increase or decrease between week 9, 13 
and 60 of the epidemic
41 1 0 9 51
IgG  100 U/ml at week 9 or 13 of the epidemic, no IgA or 
IgG 4-fold increase or decrease
40 0 3 7
Details of laboratory confirmed pertussis findings:
- IgG  100 U/ml 41 0 0 6 47
- IgA 4-fold increase 8 1 0 2 11
- IgA 4-fold increase or decrease 22 1 0 5 28
- IgG 4-fold increase 6 1 0 2 9
- IgG 4-fold increase or decrease 39 1 0 9 49
- PCR or culture positivea 50 0 0 5
No laboratory confirmed pertussis infection 22 2 3 5 d 41
a All culture and PCR positive subjects had a significant increase of IgA or IgG as well
b Pertussis cases for sensitivity calculation
c Subjects for calculations of spectrum bias in sensitivity
d Internal controls for specificity calculation
e Subjects with no cough for calculations of spectrum bias in specificity
f Subjects with asymptomatic pertussis infectionBMC Infectious Diseases 2007, 7:53 http://www.biomedcentral.com/1471-2334/7/53
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jects. One serum sample was obtained from one resident
with, and one resident without clinical pertussis. Of the
99 subjects, 51 showed a significant increase or decrease
in IgA or IgG between week 9, 13 and 60 of the epidemic,
5 of whom also had either a positive PCR or culture. Addi-
tionally, 7 subjects had a single IgG level of  100 U/ml
at week 9 or 13 of the epidemic, with no further signifi-
cant increase or decrease of IgA or IgG. This resulted in 58
subjects with, and 41 without laboratory confirmed per-
tussis infection (Table 1).
Pertussis cases for sensitivity and internal controls for 
specificity calculations
Table 1 shows the source data for the sensitivity calcula-
tions, the 46 pertussis cases (45 cases with clinical pertus-
sis coughing 14 days or more and 1 case coughing 11 days,
all with laboratory confirmed pertussis) and the 35 inter-
nal controls who had no cough and no laboratory con-
firmed pertussis infection. The mean age of the cases and
internal controls was 77 years (range: 21–86 years)  and
56 years (range: 22–91 years), respectively.
The levels of IgA and IgG obtained from the 46 pertussis
cases and the 35 internal controls are shown in Table 2.
The geometrical mean concentration (GMC) of IgA and
IgG in the 46 pertussis cases was significantly higher (p <
0.001) in all sampling weeks compared to the 35 internal
and 4275 external controls.
Course in time of IgA and IgG in pertussis cases
Figure 1 shows the longitudinal courses of the 89 IgA and
IgG concentrations obtained from the 46 pertussis cases
in weeks 9 and 13 of the epidemic, as related to the onset
(day 0) of the clinical period (coughing). Six pre-clinical
and 83 clinical serum samples were obtained from the 46
pertussis cases. The earliest serum sample was obtained 19
days before, and the latest one 87 days after the onset of
cough.
The general pattern of IgA (Figure 1a) shows a more con-
sistent increasing and decreasing pattern compared to IgG
(Figure 1b). IgG concentrations reached higher levels than
IgA concentrations and tended to decrease more rapidly to
relatively lower levels earlier in the clinical period com-
pared with IgA. From 3 of the 5 PCR or culture positive
cases (dotted lines in the figures), the first serum samples
were obtained before the onset of the cough. These 3 cases
showed at least 4-fold increases of IgA and IgG levels,
starting from below 5 U/ml.
Sensitivity and specificity of single IgA and IgG levels for 
estimating optimal cut-off values
Figure 2 shows the sensitivities of single IgA and IgG levels
calculated in the 83 serum samples obtained in week 9
and 13 of the epidemic from the 46 pertussis cases who
had been coughing for at least one day during their period
of clinical pertussis.
Sensitivities of different levels of IgA (24–74 U/ml) and
IgG (27 – 90 U/ml) ranged from 98% to 75% and 95% to
81%, respectively. The sensitivity of IgG was 80% at 100
U/ml and 71% at 200 U/ml (not shown in Figure 2).
Compared to IgG, sensitivities of IgA started higher but
decreased faster with increasing levels.
To probe spectrum bias[42] in the sensitivities obtained in
our 46 pertussis cases, we also calculated sensitivities in
the 91 IgA and 91 IgG levels obtained in weeks 9 and 13
of the epidemic of all 50 subjects with clinical pertussis,
after they had coughed for at least 1 day during their
period of clinical pertussis (Table 1). This resulted in
lower sensitivities of IgA levels (24–74 U/ml) and IgG lev-
Table 2: The Geometrical Mean Concentration (GMC), with 95% CI, of serum samples from pertussis cases and from internal controls 
at week 9, 13 and 60 of the epidemic, and of the serum samples from the external controls (n = 4275)
Subjects and time of sampling during the pertussis epidemic Number of samples IgA IgG
GMC 95% CI GMC 95% CI
Cases (n = 46)
- week 9 43 123 75 – 202 252 119 – 535
- week 13 46 172 121 – 244 355 235 – 537
- week 60 40 60 40 – 89 34 22 – 53
Internal controls (n = 35)
- week 9 34 9.4 6.4 – 13.7 6.0 3.9 – 9.3
- week 13 34 7.8 5.2 – 11.6 3.8 2.4 – 6.1
- week 60 29 6.6 4.4 – 9.9 2.8 1.8 – 4.2
- week 9, 13 and 60 combined 97 7.9 6.3 – 9.9 4.1 3.1 – 5.3
External controls (n = 4275) 4275 8.5 7.9 – 9.1 7.4 6.7 – 8.3BMC Infectious Diseases 2007, 7:53 http://www.biomedcentral.com/1471-2334/7/53
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The course of IgA and IgG Figure 1
The course of IgA and IgG. The course of IgA (figure 1a) and IgG (figure 1b) levels obtained in all 89 serum samples from 
the 46 pertussis cases obtained in week 9 and 13 of the pertussis epidemic in the convent population (n = 99). Pertussis cases 
had a laboratory confirmed B. pertussis infection and a clinical pertussis (see methods). The levels are related to the first day of 
cough of the pertussis cases. Six serum samples were obtained from cases before they started coughing and 83 samples were 
obtained from cases who had been coughing for between 1 and 87 days. Lines connect samples obtained from one subject. 
Dotted lines are from the 5 subjects with a positive culture or PCR.
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Sensitivity and specificity of IgA and IgG for estimation of optimal cut-off levels Figure 2
Sensitivity and specificity of IgA and IgG for estimation of optimal cut-off levels. Sensitivity and specificity of differ-
ent IgA (figure 2a) and IgG (figure 2b) antibody levels (U/ml) against B. pertussis from the convent population during the pertus-
sis epidemic. Sensitivities are calculated in the 83 serum samples obtained in week 9 and 13 of the epidemic, from the pertussis 
cases (n = 46) who had been coughing for between 1 and 87 days of their total period of clinical pertussis. Pertussis cases had 
a laboratory confirmed B. pertussis infection and a clinical pertussis (see methods). Specificities are calculated in the 68 serum 
samples obtained in week 9 and 13 of the epidemic from the internal controls (n = 35). Specificities of IgA and IgG levels calcu-
lated in the sera (n = 4275) of external controls (n = 4275) are indicated as well. The sensitivity en specificity mark in pertussis 
cases and internal controls of the IgA level of 24 U/ml and the IgG level of 27 U/ml with a specificity of 90% in external controls 
are indicated in black symbols.
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els (27–90 U/ml) ranging from 90% to 69% and from
87% to 73%, respectively, while the sensitivity of IgG of
100 U/ml decreased from 80% to 72%. The lower sensi-
tivities can be explained by the addition of concentrations
from three subjects with clinical pertussis who had been
coughing for 7, 11, and 21 days, respectively, and with IgA
and IgG levels of at most 14 U/ml and 4 U/ml, respec-
tively, suggesting that these three subjects did not have
pertussis infection. The addition of a fourth subject
increased the sensitivities. Indeed, this was most probably
a missed pertussis case with 255 days clinical pertussis
and highest obtained IgA and IgG levels of 116 and 80 U/
ml, and a 3.6-fold decrease of IgG, while we used a 4-fold
change in our case definition. A 3-fold change has been
accepted as significant in a sufficiently precise assay.[43]
The specificities calculated in the 68 concentrations in
serum samples obtained from the 35 internal controls in
the convent population at weeks 9 and 13 of the epidemic
are shown in Figure 2. Specificities of different levels of
IgA (24–74 U/ml) and IgG (27–90 U/ml) levels ranged
from 82% to 94% and 89% to 99%, respectively. The spe-
cificity of IgG was 100% at 100 U/ml. The specificities of
different levels of IgA (24–74 U/ml) and IgG (27–90 U/
ml) from 4275 sera samples from the 4275 external con-
trols ranged from 90 to 99% (Figure 2). In the external
controls IgA levels showed higher specificities than similar
IgG levels.
To probe spectrum bias in the specificities obtained in our
35 internal controls, we calculated specificities as well in
the 90 IgA and IgG concentrations obtained in weeks 9
and 13 of the epidemic of all 47 subjects with no cough
(Table 1). This resulted in lower specificities of different
levels of IgA (24–74 U/ml) and IgG (27–90 U/ml) rang-
ing from 71% to 85% and 72% to 90%, respectively. The
specificity of 100 U/ml IgG decreased from 100% to 92%.
The lower observed IgA specificities were due to the high
levels from the 12 added subjects with a laboratory con-
firmed pertussis infection and without a pre-epidemic
cough or a clinical pertussis. Indeed, 15 of the 22 IgA lev-
els from these 12 subjects were at least 24 U/ml, and of the
IgG levels, 18 of 22 were at least 27 U/ml, and 8 were at
least 100 U/ml. So the added 12 subjects were not a true
control group of unexposed and uninfected subjects.
Sensitivities at different time intervals
Table 3 shows the sensitivities of IgA (24–74 U/ml) and
IgG (27–90 U/ml) levels calculated from the 46 pertussis
cases (see Figure 2) at different time intervals in reference
to the first day of coughing. In the first two weeks after the
onset of clinical pertussis, cut-off levels of 24 U/ml for IgA
Table 3: Specificities in external controls (n = 4275) and sensitivities in time intervals in reference to the onset of cough in pertussis 
cases (n = 46) of single IgA and IgG concentrations (see Figure 2). Geometrical Mean Concentrations (GMC) and number of samples 
are indicated.
Level (U/ml)a Specificity 
external 
controls
Sensitivity (%) in time intervals with reference to the onset of cough
-21 to 0 days 1 to 14 days 15 to 21 days 22 to 87 days 1 to 87 days
IgA
24 90.0% 33 100 100 97 98
40 95.0% 33 63 82 95 90
52 97.5% 17 63 82 92 88
74 99.0% 17 63 64 78 75
GMC (U/ml) 11 60 136 212 177
IgG
27 90.0% 33 75 100 97 95
41 95.0% 33 75 91 95 93
65 97.5% 33 50 82 94 87
90 99.0% 33 38 82 86 81
100b 99–100% 33 38 82 84 80
GMC (U/ml) 84 8 3 9 0 5 0 6 3 9 1
No. samples 6 8 11 64 83
a Levels are obtained from the estimation of optimal cut-off values in Figure 2.
b Used by the National Institute for Public Health and the Environment in The Netherlands for surveillance.BMC Infectious Diseases 2007, 7:53 http://www.biomedcentral.com/1471-2334/7/53
Page 8 of 11
(page number not for citation purposes)
and 27 U/ml for IgG showed sensitivities of 100% and
75%, respectively. In the third week of infection, a sensi-
tivity of 100% was calculated for both parameters. From
the fourth week onwards, the sensitivity remained at 97%.
Waxing and waning of IgA and IgG between diagnostic 
parameters
It was estimated that IgA reached the 100% sensitivity and
99% specificity levels earlier than IgG. IgG waned more
quickly back towards pre-infection levels. IgA and IgG
remained above their 100% sensitivity level during 7.2
and 5.1 months respectively and above their 99%-specifi-
city level during 5.5 and 4.3 months, respectively (Table
4). The rate of increase of IgA and IgG levels indicates that
the paired samples should be collected within 4 and 7
days, respectively, after they begin to increase in order to
observe the fourfold rise towards their GMC.
Discussion
Early diagnosis of pertussis in adults for outbreak manage-
ment requires low cut-off levels for single IgA and IgG
serological tests. We found that cut-offs of 24 U/ml for IgA
and 27 U/ml for IgG led to a specificity of 90% and a sen-
sitivity of 100% and 75%, respectively, during the first 2
weeks of pertussis. In the third week, the sensitivity was
100% for both tests. The sensitivity decreased slightly to
98% for IgA, and 95% for IgG during the first 87 days of
clinical pertussis. After acute onset of pertussis, IgA
remained above 24 U/ml for a mean duration of 7.2
months, and IgG remained above 27 U/ml for a mean
duration of 5.1 months.
Although this study is limited by the relatively small
number of subjects, the results are based on a pertussis
epidemic in a defined community, with 100% participa-
tion. We are not aware of another study in which sensitiv-
ities of single IgA and IgG were evaluated in both the pre-
clinical and clinical phases of pertussis.
The definition of pertussis was partly based on single IgA
and IgG levels, which were also evaluated as diagnostic
marker. This may have caused some incorporation
bias.[42,44] However, 42 of the 46 pertussis cases were
based on at least 4-fold changing IgA or IgG levels in
paired samples (Table 1). The lowest IgG level of the 4
cases identified with a single IgG sample was 376 U/ml
and they had coughed between 44 – 263 days. From 3 of
these 4 cases we were not able to obtain a third serum
sample in week 60 (2 subjects died earlier with pertussis),
in order to detect significant change. The fourth subject
showed a 3.6-fold changing IgG level. In addition, we did
not find other causes of this epidemic of cough[12] in the
ideal epidemic circumstances of a convent population
with positive cultures for B. pertussis.
In our evaluation of spectrum bias in sensitivity and spe-
cificity, we showed that our choice of pertussis cases and
controls was sound. Arguably, the use of our 35 internal
controls may have led to underestimation of the specifi-
city of single low IgA and IgG levels. Indeed 7 of the 35
internal controls had high IgA levels ranging from 24 – 74
U/ml and 2 internal controls had IgA levels above 74 U/
ml. Six internal controls had IgG levels ranging from 27 –
Table 4: Estimated waxing and waning of IgA and IgG levels between diagnostic parameters
Variable IgA IgG
Laboratory detection limit 5 U/ml 5 U/ml
100% sensitivity level in the 46 pertussis cases 24 U/ml 27 U/ml
90% specificity level in 4275 external controls 24 U/ml 27 U/ml
99% specificity level in 4275 external controls 74 U/ml 90 U/ml
GMC of the highest level obtained in week 9 and 12 of pertussis cases with at least 4-fold increase or 
decrease between week 9, 13 and 60 of the epidemic
229 U/ml
(n = 28 levels)
406 U/ml
(n = 49 levels)
Average speed of significant increase 16.0 U/ml/day
(n = 11 level pairs)
14.7 U/ml/day
(n = 9 level pairs)
Average speed of significant decrease 1.0 U/ml/day
(n = 18 level pairs)
2.9 U/ml/day
(n = 46 level pairs)
Mean time to increase from detection limit to 100% sensitivity level 1.2 days 1.5 days
Mean time to increase from detection limit to 99% specificity level 4.3 days 5.8 days
Mean time to increase from detection limit to GMC 14.0 days 27.3 days
Mean time to increase from 99% specificity level to GMC 9.8 days 21.5 days
Mean time to decrease from GMC to 99% specificity level 156.0 days 109.0 days
Mean time spent above 99% specificity level 165.8 days
(5.5 month)
130.5 days
(4.3 month)
Mean time to decrease from 99% specificity level to 100% sensitivity level 50.0 days 21.7 days
Total time spent going up and down between detection limit and GMC 238.0 days 165.6 days
Total time spent going up and down between 100% sensitivity level and GMC 217.8 days
(7.2 months)
156.5 days
(5.1 months)BMC Infectious Diseases 2007, 7:53 http://www.biomedcentral.com/1471-2334/7/53
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90 U/ml and one internal control above 90 U/ml. We
argue that IgA levels above 24 U/ml and IgG levels above
27 U/ml decreased the specificities obtained in the inter-
nal controls, compared with the specificities obtained in
the external controls (Figure 2). Among all 47 subjects
with no cough (Table 1), 21 (45%) had high single IgA
and/or IgG levels. Because these 21 subjects with high sin-
gle IgA and/or IgG levels had a serological indication of
infection (antibody boosting) without symptoms, we
consider the external control group, with GMC of IgA and
IgG levels significantly lower than in the 46 pertussis
cases, the better choice for calculating specificities.
The retrospective part of the study may have resulted in
recall bias regarding onset of cough. The study however,
was supported by a nun who was responsible for looking
after all the nuns with pertussis during the epidemic. This
registered nurse kept reliable clinical records including the
history of coughing before and after the start of the study.
We are therefore fairly confident that recall bias is limited.
IgA antibodies to B. pertussis antigens in whole-cell soni-
cate is known to lack specificity[45] compared to IgA anti-
bodies to pertussis toxin.[30] Indeed, single high values of
IgA and IgG antibodies to pertussis toxin indicate infec-
tions in adults, and IgA is more indicative of a recent anti-
body response, although less consistent than IgG.[30]
However, we excluded causes of the epidemic other than
pertussis and used culture, PCR, and IgG against pertussis
toxin to positively identify pertussis cases. In our external
control group, the levels of IgA against whole cell sonicate
showed higher specificities than similar IgG levels. In the
original Dutch study of IgA antibodies, it was stated that
IgA antibodies, which are not induced by vaccination, can
be used as a reliable indicator of natural infection with B.
pertussis in adults within one week of infection,[38] espe-
cially if interpreted in connection with clinical find-
ings.[46] On the other hand it has been postulated that
because of the prolonged antibody response, IgA is not
such a useful marker for recent infection.[38] We esti-
mated however, that IgA reaches 100% sensitivity and
99% specificity level sooner than IgG, and that IgA and
IgG remain above the 99% specificity level for a mean
duration of 5.5 and 4.3 months, respectively, after the
onset of pertussis.
IgG antibodies against the virulence factors pertussis
toxin, pertactin, and fimbriae increase and decrease after
both natural infection and vaccination.[31,47-49] In bac-
teriologically proven pertussis cases, IgG antibodies
declined more rapidly than IgA.[31] This was confirmed
in our study. IgG levels of at least 25 IU/ml were associ-
ated with B. pertussis infection in a previous study.[31] In
our study, a cut-off level of 27 U/ml for IgG resulted in a
sensitivity of 100% the third week after the onset of per-
tussis symptoms, and remained at 97% up to the 13th
week with a specificity of 90%.
We determined a sensitivity of 90% for 50 U/ml IgG and
of 80% for 100 U/ml, which is comparable to a previous
evaluation that determined a sensitivity of 89% for IgG
levels above 50 U/ml and 76% for IgG levels of  100 U/
ml.[35] Also, our specificity of 99% for an IgG level of 90
U/ml is comparable to that found in the prior study[35]
which concluded that, independent of age, a cut-off level
of 100 U/ml IgG showed a specificity of 99–100%. In the
prior study, most patients reached IgG levels of 100 U/ml
within 4 weeks of disease onset which persisted for 4.5
months. These findings are in line with our estimates that
the IgG level increases from the detection limit (5 U/ml)
to 100 U/ml in 6.7 days and persists at this level for 4.2
months. The rate of IgA and IgG increase underlines the
importance of obtaining acute phase samples early in the
disease in order to detect a significant increase, and conse-
quently the importance of significantly decreasing levels
for ultimately diagnosing pertussis if the first sample is
not obtained early in the disease.[33,34] Our outcomes
are also in line with a study in which a cut-off point of 94
IU/ml for IgG pertussis toxin, with a sensitivity of 80%
and a specificity of 93%, has been proposed.[50] This 94
IU/ml is comparable with 76 U/ml in our study and con-
siderable lower then the 125 IU/ml (= 100 U/ml) offi-
cially used in the Netherlands. In our study 94 IU IgG
pertussis toxin had a sensitivity of 83% and a specificity of
98%.
Our findings for low IgA and IgG levels to diagnose per-
tussis in outbreak management are supported by findings
from a pertussis outbreak in a boarding school in Aus-
tralia, where IgA against whole-cell sonicate, and IgG
against pertussis toxin proved useful for early diagnosis
and outbreak management. In that study, it was con-
cluded that the IgG level of 125 IU/ml (100 U/ml) was
not sensitive enough to identify pertussis cases in their
early stages for outbreak management.[51]
Because IgA is not induced by vaccination against pertus-
sis, it may be preferred over IgG in recently vaccinated
subjects, as IgG is induced by vaccination with whole-cell
vaccines against pertussis used in the Netherlands.[31]
Other vaccines may induce even higher IgG-pertussis
toxin levels, since the response to pertussis toxin varies
between different whole-cell vaccines and acellular vac-
cines. These IgG-pertussis toxin levels can reach levels
higher than 100 U/ml.[48,52-54]
Conclusion
High sensitivity and specificity are required to track and
exclude pertussis in vaccine efficacy trials[43] if another
serious disease is suspected, and in passive surveillanceBMC Infectious Diseases 2007, 7:53 http://www.biomedcentral.com/1471-2334/7/53
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systems used to estimate vaccine efficacy. In clinical prac-
tice and outbreak situations, diagnosis of B. pertussis ill-
ness must be immediate to allow for prompt therapeutic
intervention to reduce disease severity and spread. There-
fore, diagnostic criteria should be sensitive, even if specif-
icity is compromised.[55] Pertussis has recognizable
characteristic clinical symptoms to a physician.[56] A clin-
ical case definition can be used in clinical practice and
outbreak management,[57,58] and for antibiotic manage-
ment.[59] We conclude that after infection with B. pertus-
sis IgA and IgG concentrations start to increase from low
levels upwards, and that low cut-off levels of 24 U/ml for
IgA antibodies and 27 U/ml (equivalent to 27 IU/ml) for
IgG antibodies could be considered as practical tools for
laboratory confirmation of clinical pertussis in adults dur-
ing the first 3 weeks of disease outbreak for public health
practice, e.g. outbreak management. We suggest a more
extensive study of the value of IgA antibodies to pertussis
toxin for the early diagnosis of pertussis.
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